Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 751,428
  • Shares Outstanding, K 28,007
  • Annual Sales, $ 219,790 K
  • Annual Income, $ -57,470 K
  • EBIT $ 8 M
  • EBITDA $ 15 M
  • 60-Month Beta 0.92
  • Price/Sales 3.45
  • Price/Cash Flow N/A
  • Price/Book 1.72

Options Overview Details

View History
  • Implied Volatility 78.33% ( +4.71%)
  • Historical Volatility 44.44%
  • IV Percentile 67%
  • IV Rank 52.52%
  • IV High 134.09% on 07/15/24
  • IV Low 16.64% on 05/21/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 5
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 1,923
  • Open Int (30-Day) 2,098

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +120.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.82 +2.87%
on 12/30/24
32.60 -18.53%
on 12/06/24
-3.72 (-12.29%)
since 11/29/24
3-Month
25.82 +2.87%
on 12/30/24
35.84 -25.89%
on 11/05/24
-1.96 (-6.87%)
since 09/30/24
52-Week
16.97 +56.56%
on 07/05/24
35.84 -25.89%
on 11/05/24
+4.98 (+23.08%)
since 12/29/23

Most Recent Stories

More News
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the treatment...

CTMX : 1.0150 (-5.14%)
CSTL : 26.40 (-1.60%)
SPRO : 1.0099 (-1.95%)
MNMD : 6.55 (-4.24%)
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...

IMCR : 28.92 (-0.89%)
CRSP : 38.90 (-2.80%)
GLUE : 7.00 (-0.85%)
CSTL : 26.40 (-1.60%)
RIGL : 16.40 (-0.61%)
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome...

CTMX : 1.0150 (-5.14%)
RARE : 42.03 (-3.20%)
CSTL : 26.40 (-1.60%)
SPRO : 1.0099 (-1.95%)
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche RHHBY announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind...

CSTL : 26.40 (-1.60%)
PRTA : 14.77 (-2.44%)
RHHBY : 35.2175 (+0.42%)
SPRO : 1.0099 (-1.95%)
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The...

KRYS : 157.90 (-0.87%)
CTMX : 1.0150 (-5.14%)
CSTL : 26.40 (-1.60%)
SPRO : 1.0099 (-1.95%)
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic...

CTMX : 1.0150 (-5.14%)
EWTX : 27.42 (-4.59%)
CSTL : 26.40 (-1.60%)
SPRO : 1.0099 (-1.95%)
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns

Investors seek companies that consistently generate profits. One of the best metrics to measure profitability is the net profit margin. This metric highlights a company's ability to convert sales into...

STRA : 92.49 (-0.34%)
CSTL : 26.40 (-1.60%)
ESEA : 33.88 (-2.45%)
QFIN : 37.68 (-1.31%)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 1.0150 (-5.14%)
CSTL : 26.40 (-1.60%)
EDIT : 1.1900 (-1.65%)
SPRO : 1.0099 (-1.95%)
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating...

KRYS : 157.90 (-0.87%)
CTMX : 1.0150 (-5.14%)
CSTL : 26.40 (-1.60%)
SPRO : 1.0099 (-1.95%)
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart  one in atopic dermatitis (AD or eczema)...

CTMX : 1.0150 (-5.14%)
CSTL : 26.40 (-1.60%)
QTTB : 3.19 (-5.06%)
SPRO : 1.0099 (-1.95%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 28.32
2nd Resistance Point 27.92
1st Resistance Point 27.37
Last Price 26.40
1st Support Level 26.43
2nd Support Level 26.03
3rd Support Level 25.48

See More

52-Week High 35.84
Fibonacci 61.8% 28.63
Fibonacci 50% 26.40
Last Price 26.40
Fibonacci 38.2% 24.18
52-Week Low 16.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar